In a paper that has just appeared in the journal Science Translational Medicine, researchers led by LMU’s Professor Christian Weber and Dr. Philipp von Hundelshausen now report the results of the first ever systematic survey of direct interactions between individual chemokines and characterized their biological effects.
“In the course of our study, we were able to demonstrate that specially designed synthetic peptides selectively inhibit the ability of CC heterodimers to promote the development of atherosclerosis and acute inflammation of the lung, or mimic the capacity of CXC heterodimers to inhibit platelet aggregation, thus limiting the risk of thrombosis”, Weber says. Appropriately designed peptides could therefore serve as the basis for the creation of new anti-inflammatory and anti-platelet compounds without side effects.
read further:
https://www.en.uni-muenchen.de/news/newsarchiv/2017/weber_chemokine.html
https://www.uni-muenchen.de/forschung/news/2017/weber_chemokine.html
